Organon - About the company
Organon is an acquired company based in Jersey City (United States), founded in 1923 by Wiktor Dachnowski. It operates as a Dutch traditional pharma company acquired by Merck. , with last known valuation of $*****. The company has 1872 active competitors, including 95 funded and 204 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.
Company Details
Organon was a Dutch traditional pharma company acquired by Merck & Co. The company had products in areas of reproductive medicine, contraception, psychiatry, HRT, and anesthesia. It was acquired by Schering-Plough Corporation in 2007. Schering-Plough later merged with Merck & Co in 2009.In 2021, the company recorded annual revenues of $6.47B and a net profit of $1.35B
- Website
- www.organon.com/
- Registered Address
- 6, Bredgade, København K, 1260
Key Metrics
Founded Year
1923
Location
Jersey City, United States
Stage
Acquired
Last Known Valuation
$***** as on Apr 26, 2026
Ranked
72nd among 1872 active competitors
Annual Revenue
$1B+ as on Dec 31, 2025
Employee Count
6,911 as on Oct 31, 2026
Exit Details
Acquired by Sun Pharma (Apr 26, 2026)
Legal entities associated with Organon
Organon is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ORGANON & CO. CIN: 32084723132 , United States, Active | Jun 23, 2022 | - | - | - |
Organon Denmark ApS CIN: 41193093 , Denmark, Active | Feb 23, 2020 | - | 15 (As on Aug 31, 2024) | |
Organon Pharma d.o.o. CIN: 24886309951 , Croatia, Active | Apr 20, 2020 | €1M - €10M (As on Dec 31, 2024) | - | |
ORGANON & CO. CIN: 1821825 , United States, Active | Mar 10, 2020 | $1B+ (As on Dec 31, 2025) | - | - |
Organon's acquisition details
Organon got acquired by Sun Pharma on Apr 26, 2026.
Click here to take a look at Organon's acquisition in detail
Sign up to download Organon's company profile
Organon's funding and investors
Organon is a funded company.
Organon's founders and board of directors
Founder? Claim ProfileThe founders of Organon is Wiktor Dachnowski.
Here are the details of Organon's key team members:
- Wiktor Dachnowski: Founder, Global Business Technology Service Management and Command Center Lead of Organon.
- Ken Frazier: CEO of Organon.
View details of Organon's Founder profiles and Board Members
Organon's employee count trend
Organon has 6,911 employees as of Oct 26. Here is Organon's employee count trend over the years:
Uncover Organon's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Organon's Competitors and alternates
Top competitors of Organon include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Organon, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 83/100 | |
2nd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 79/100 | |
4th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 74/100 | |
7th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
9th |  Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
10th | Genentech 1976, San Francisco (United States), Acquired | R&D company focused on manufacturing drugs for multiple therapeutic areas | $72.5M | 68/100 | |
72nd | Organon 1923, Jersey City (United States), Acquired | Dutch traditional pharma company acquired by Merck | - | - | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Organon's competitors? Click here to see the top ones
Organon's Investments and acquisitions
Organon has made 1 investments in companies including Claria Medical. Organon has also acquired 4 companies including Dermavant and Forendo Pharma.Here is the list of investments & acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Sep 18, 2024 | Acquisition | 2016 | Phoenix (United States) | |
Jan 05, 2023 | Investments | 2017 | Mountain View (United States) | |
Nov 11, 2021 | Acquisition | 2013 | Turku (Finland) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by Organon
Reports related to Organon
Here is the latest report on Organon's sector:
News related to Organon
Filter this listMedia has covered Organon for a total of 63 events in the last 1 year, 22 of them have been about company updates and 4 about partnerships.
•
Sun Pharma Q2 Net Profit Drops 36.2% Due to Organon Acquisition CostsIndiatimes•Oct 30, 2026•Sun Pharma, Organon
•
Sun Pharma Plans ₹10,000 Crore Bond Sale to Refinance Organon Acquisition LoanMint•Sep 29, 2026•Sun Pharma, Organon
•
•
Organon Announces Two Her Health Grants in India for Adolescent Girls' Health and Women's Contraceptive AccessBusiness Wire India•Sep 19, 2026•Organon
•
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine DeviceBusiness Wire•Sep 14, 2026•Organon
•
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial AvailabilityBusiness Wire•Aug 11, 2026•Organon
•
Organon reports new findings from Vtama atopic dermatitis trialshttps://www.clinicaltrialsarena.com/•Jul 27, 2026•Organon
•
Sun Pharma inches closer to biggest-ever buyout as Organon shareholders approve mergerMoneycontrol•Jul 24, 2026•Sun Pharma, Organon, Immuneel
•
Organon Canada Announces Appointment of Dominic Bégin as President and Managing DirectorCNW•Jul 22, 2026•Organon
•
Organon Licenses Hormone-Free Copper IUD MIUDELLA for Global CommercializationFemtech Insider•Jul 07, 2026•Organon
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Organon
Explore our recently published companies
- Genomain - Sweden based, 2015 founded, Unfunded company
- OZER Advanced Technologies - Voorheesville based, 2000 founded, Unfunded company
- Vennekretsen - United States based, Unfunded company
- spurmicro.com - Unfunded company
- Saguna - Unfunded company
- Amplifier IC Chips - 2018 founded, Unfunded company
